Abbvie Inc. (ABBV) Files Form 4 Insider Selling : Carlos Alban Sells 47,438 Shares

Abbvie Inc. (ABBV): Carlos Alban , EVP, Commercial Operations of Abbvie Inc. sold 47,438 shares on May 10, 2016. The Insider selling transaction was reported by the company on May 12, 2016 to the Securities and Exchange Commission. The shares were sold at $63.52 per share for a total value of $3,013,261.75 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 8, 2016, Laura J Schumacher (Executive Vice President) sold 25,000 shares at $56.12 per share price.On Jul 31, 2015, Richard A Gonzalez (Chairman of the Board and CEO) sold 40,021 shares at $71.25 per share price.Also, On May 21, 2015, Thomas A. Hurwich (VP, Controller) sold 6,200 shares at $66.00 per share price.On Mar 3, 2015, Azita Saleki-gerhardt (SVP, Operations) sold 2,112 shares at $60.47 per share price.

AbbVie Inc: On Tuesday, May 10, 2016 heightened volatility was witnessed in AbbVie Inc which led to swings in the share price. The shares opened for trading at $63.51 and hit $63.76 on the upside , eventually ending the session at $63.74, with a gain of 0.06% or 0.04 points. The heightened volatility saw the trading volume jump to 1,21,03,393 shares. The 52-week high of the share price is $71.6 and the company has a market cap of $103,090 M . The 52-week low of the share price is at $45.45.

AbbVie Inc Money Flow Index Chart

Company has been under the radar of several Street Analysts.AbbVie Inc is Initiated by Societe Generale to Sell and the brokerage firm has set the Price Target at $47. The Rating was issued on Apr 6, 2016.AbbVie Inc is Initiated by Deutsche Bank to Hold and the brokerage firm has set the Price Target at $63. The Rating was issued on Mar 15, 2016.AbbVie Inc is Upgraded by Citigroup to Buy. Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on Feb 23, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.